Literature DB >> 23542459

Early-stage pulmonary adenocarcinoma (T1N0M0): a clinical, radiological, surgical, and pathological correlation of 104 cases. The MD Anderson Cancer Center Experience.

Annikka Weissferdt1, Neda Kalhor, Edith M Marom, Marcelo F Benveniste, Myrna C Godoy, Arlene M Correa, Stephen G Swisher, Cesar A Moran.   

Abstract

The recent proposal for histological subtyping of pulmonary adenocarcinoma by predominant pattern and introduction of the terms adenocarcinoma in situ and minimally invasive adenocarcinoma to replace the term bronchioloalveolar carcinoma by the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society has led us to conduct a study of 104 patients with early-stage primary pulmonary adenocarcinoma (T1N0M0), with a view to histological subtype as defined by the new proposal and clinical outcome. None of the clinical parameters of our patient population (type of surgery, age, gender, tumor size, and comorbidities) showed any statistically significant correlation with outcome, except for associated malignancies, which not surprisingly appeared to have a negative impact on survival. In addition, statistical analyses of the histological characteristics to include tumor differentiation and the percentage of a lepidic or bronchioloalveolar component did not show any statistically significant values in terms of survival. Our results failed to show any statistically significant difference of survival between those T1N0M0 adenocarcinomas with a lepidic component and those without, thus questioning the use of terms such as in situ or minimally invasive adenocarcinoma. On the basis of our results, we consider that the outcome for patients with T1N0M0 disease is still best determined by appropriate staging rather than by changes in the pathology nomenclature of adenocarcinoma.

Entities:  

Mesh:

Year:  2013        PMID: 23542459     DOI: 10.1038/modpathol.2013.33

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  2 in total

Review 1.  Reclassification of early stage pulmonary adenocarcinoma and its consequences.

Authors:  Annikka Weissferdt; Cesar A Moran
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

2.  Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease.

Authors:  Kyuichi Kadota; Jonathan Villena-Vargas; Akihiko Yoshizawa; Noriko Motoi; Camelia S Sima; Gregory J Riely; Valerie W Rusch; Prasad S Adusumilli; William D Travis
Journal:  Am J Surg Pathol       Date:  2014-04       Impact factor: 6.394

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.